We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Regulatory News (ZTF)

Share Price Information for Zotefoams (ZTF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 420.00
Bid: 413.00
Ask: 424.00
Change: 30.00 (7.69%)
Spread: 11.00 (2.663%)
Open: 410.00
High: 420.00
Low: 406.00
Prev. Close: 420.00
ZTF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

High-performance foam in medical facility doors

27 Apr 2023 07:00

RNS Number : 6037X
Zotefoams PLC
27 April 2023
 

27 April 2023

Zotefoams plc

("Zotefoams" or "Group")

 

Agreement to supply high-performance foam for use in medical facility doors

Zotefoams, a world leader in cellular materials technology, is pleased to announce an agreement with Kennon Products (Wyoming, USA) to supply ZOTEK® F high-performance foam for use in Kennon's newest ligature-resistant patient safety door, broadening the scope of application for this material. So-called breakaway doors are used in medical facilities to protect vulnerable patients from self-harm while affording privacy.

Produced exclusively by Zotefoams and manufactured from PVDF (polyvinylidene fluoride), ZOTEK F is best-known as a disruptive material that has enabled airframe manufacturers and airlines to reduce carbon consumption by shedding significant weight from aircraft interiors. Equally important are the safety credentials of the material: PVDF is inherently inert, and Zotefoams' proprietary method of foam manufacture does not affect that essential purity. Accordingly, ZOTEK F achieves the highest ratings for its Fire, Smoke and Toxicity (FST) properties and also exhibits excellent resistance to mould and bacteria growth.

Safety is the foremost consideration in the design of the Kennon Door 2.0. The softness of ZOTEK F and its light weight combine with breakaway magnetic hinges to save lives, as do its resistance to flame and - in the event of ignition - low smoke output. The durable design of the door also enhances the look of any facility.

Kennon achieved its primary objective, that of developing a door that achieves the USA's new National Fire Protection Association NFPA-286 certification, which is required for facility operators wishing to meet certain fire prevention guidelines.

"The unique properties of ZOTEK F foam are a key reason for our anti-ligature doors meeting the NFPA-286 standard," said Kennon CEO, Joe Wright. "Our partnership with Zotefoams has been a mutual success and together we're helping to save lives in behavioural health hospitals."

David Stirling, Zotefoams Group CEO, commented, "We were pleased to work closely with Kennon on this project, selecting and testing various ZOTEK F materials, while providing support and insight based on our previous experience of aviation applications and flame testing.

"This application has produced another 'first' for ZOTEK F and demonstrates the potential of the material to deliver benefits well beyond its current core markets of aviation and aerospace."

* ENDS *

 

 

Enquiries:

 

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

 

IFC Advisory (Financial PR & IR)

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA, Stilling, Denmark (microcellular foam technology) and Jiangsu Province, China (T-FIT).

www.zotefoams.com

 

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAIFMFTMTATBBJ
Date   Source Headline
19th Apr 20247:00 amRNSExclusivity agreement with Design Blue Limited
19th Apr 20247:00 amRNS2023 Annual Report & Notice of 2024 AGM
12th Apr 20244:34 pmRNSNotification Of Transactions Of Directors/PDMRs
28th Mar 20247:00 amRNSDirector/PDMR Shareholding
26th Mar 20248:36 amRNSReplacement Notice Transactions Of Directors/PDMRs
26th Mar 20247:00 amRNSGroup CEO succession
25th Mar 20245:58 pmRNSNotification Of Transactions Of Directors/PDMRs
22nd Mar 20245:31 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSPreliminary Results
12th Mar 20241:41 pmRNSNotification Of Transactions Of Directors/PDMRs
14th Feb 20247:00 amRNSZotefoams joins independent authority, RECOUP
13th Feb 202412:31 pmRNSNotification Of Transactions Of Directors/PDMRs
7th Feb 20247:00 amRNSNotice of results and investor presentation
5th Feb 20241:20 pmRNSHolding(s) in Company
22nd Jan 20241:58 pmRNSHolding(s) in Company
18th Jan 20247:00 amRNSFull Year Trading Update
12th Jan 20245:13 pmRNSDirector/PDMR Shareholding
12th Jan 202412:28 pmRNSNotification Of Transactions Of Directors/PDMRs
5th Jan 202412:47 pmRNSReplacement Holding(s) in Company
4th Jan 20243:24 pmRNSHolding(s) in Company
4th Jan 20241:17 pmRNSHolding(s) in Company
13th Dec 20234:49 pmRNSHolding(s) in Company
13th Dec 20234:31 pmRNSReplacement Notice Transactions Of Directors/PDMRs
13th Dec 20231:54 pmRNSHolding(s) in Company
12th Dec 20233:46 pmRNSNotification Of Transactions Of Directors/PDMRs
12th Dec 202312:45 pmRNSNotification Of Transactions Of Directors/PDMRs
11th Dec 20231:53 pmRNSNotification Of Transactions Of Directors/PDMRs
27th Nov 20237:00 amRNSTop industry award for ReZorce® beverage cartons
14th Nov 202311:56 amRNSNotification Of Transactions Of Directors/PDMRs
8th Nov 20235:38 pmRNSHolding(s) in Company
7th Nov 20237:01 amRNSGroup CEO succession
7th Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSZotefoams programme extension at Nike
12th Oct 202312:09 pmRNSNotification Of Transactions Of Directors/PDMRs
11th Oct 20239:47 amRNSNotification Of Transactions Of Directors/PDMRs
29th Sep 20237:00 amRNSBoard Changes
18th Sep 20234:45 pmRNSHolding(s) in Company
12th Sep 202310:57 amRNSNotification Of Transactions Of Directors/PDMRs
5th Sep 20234:07 pmRNSHolding(s) in Company
31st Aug 20233:14 pmRNSHolding(s) in Company
29th Aug 20237:00 amRNSInvestor presentation on Investor Meet Company
25th Aug 20237:00 amRNSIssue of Equity
14th Aug 20231:51 pmRNSNotification of Transactions of Directors/PDMRs
9th Aug 20233:29 pmRNSHolding(s) in Company
8th Aug 20237:00 amRNSInterim Results
19th Jul 20231:29 pmRNSHolding(s) in Company
18th Jul 20237:00 amRNSJoint development agreement for ReZorce®
12th Jul 202311:01 amRNSNotification Of Transactions Of Directors/PDMRs
10th Jul 20237:00 amRNSNotice of results and investor presentation
22nd Jun 20232:20 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.